miR 488* inhibits androgen receptor expression in prostate carcinoma cells
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Androgen receptor (AR) is a ligand‐dependent transcription factor, which plays a significant role in prostate carcinogenesis. Blockade of AR and its ligand, androgen is the basis for the treatment of prostate cancer (PCa). Nevertheless, a modest increase in the critical levels of AR mRNA and corresponding protein is sufficient for the development of resistance to antiandrogen therapy. A strategy to further downregulate AR mRNA and protein expression in combination with antiandrogen therapy may prevent or delay the development of androgen‐independent PCa. Recent studies show that microRNAs (miRNAs) perform tumor suppressor functions in various cancers. In this study, we demonstrate that the overexpression of miR 488* downregulates the transcriptional activity of AR and inhibits the endogenous AR protein production in both androgen‐dependent and androgen‐independent PCa cells. In addition, miR 488* blocks the proliferation and enhances the apoptosis of PCa cells. Our data indicate that miR 488* targets AR and is a potential modulator of AR mediated signaling. Our findings provide insight for utilizing miRNAs as novel therapeutics to target AR in PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Prediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 5,199
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020363 · Cited by 3,796 · cited 1×
“To identify potential miRNAs which can regulate AR, we used PicTar,(37) TargetScan,(38) and miRanda.(39) Only TargetScan identified a putative binding site for miR 488* in the 3’ UTR of human AR.”
MethodA Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626 · cited 1×
“Although the expression of these miRNAs in normal human tissues and disease states has not been extensively studied, miR 488* and miR 488 have been reported to be predominantly expressed in human brain tissues.(40,46) We failed to detect the”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 2×
“The alternative survival pathways that bypass the AR-signaling cascade have been found to mainly include the upregulation of anti-apoptotic molecules.(7,8,45) Our results are consistent with previous reports.”
BackgroundResultDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Identification of hundreds of conserved and nonconserved human microRNAs
Bentwich, I., Avniel, A., Karov, Y., Aharonov, R., Gilad, S., Barad, O., Barzilai, A., Einat, P., Einav, U., Meiri, E., et al. (2005) · Nature Genetics · doi:10.1038/ng1590 · Cited by 1,841
Wright, M. E., Tsai, M.-J., & Aebersold, R. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0031 · Cited by 166 · cited 1×
“Other strategies being explored for lowering AR expression include targeting AR mRNA expression by using ribozyme,(11,18) antisense oligonucleotides, short hairpin RNA (shRNA)(22) and small interfering RNAs (siRNAs).(12,14,15,23,24) In this article, we have evaluated a microRNA (miRNA) based approach for the suppressi…”
Method
Cited by
Androgen receptor signaling in prostate cancer
Culig, Z., & Santer, F. R. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9474-0 · Cited by 283
“AR is a target for miRNA-488 which has anti-proliferative and proapoptotic properties in prostate cancer [51].”
BackgroundSystematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells
Östling, P., Leivonen, S.-K., Aakula, A., Kohonen, P., Mäkelä, R., Hagman, Z., Edsjö, A., Kangaspeska, S., Edgren, H., Nicorici, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2421 · Cited by 270
The role of androgens and the androgen receptor in cycling endometrium
Cloke, B., & Christian, M. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.031 · Cited by 77
miRNAs as therapeutic tools and biomarkers for prostate cancer
Arrighetti, N., & Beretta, G. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030380 · Cited by 43
Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers
Fletcher, C. E., Dart, D. A., & Bevan, C. L. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0208 · Cited by 37
“Similarly, AR levels were decreased both at the RNA and protein level following ectopic expression of miR-488* in androgen-dependent and -independent prostate cancer cells, and both AR transcriptional activity and AR 30-UTR reporter activity were also reduced (Sikand et al. 2011a).”
Background
Metadata
- Authors
- Sikand, K., Slaibi, J. E., Singh, R., Slane, S. D., & Shukla, G. C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-06-24
- Volume
- 129
- Issue
- 4
- Pages
- 810-819
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2031257439
- Cited by
- 124
- References
- 10
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.